Congress (U.S. Legislature)

Recent Law Expands Orphan Drug Protections, Shielding Blockbusters from Medicare Price Negotiations

2 weeks ago talkbio0Tagged Big Beautiful Bill, Congress (U.S. Legislature), Drug Industry, drug price, Inflation Reduction Act, Keytruda, Medicare, negotiation, OBBBA, Opdivo, orphan drug exclusion

orphan drug exclusion; Medicare negotiation; One Big Beautiful Bill; Keytruda; Opdivo; Inflation Reduction Act; OBBBA; drug pricing; Congress; pharmaceutical industry

RFK Jr. Cancels USPSTF Meeting Amid Healthcare Groups’ Integrity Concerns

3 months ago talkbio0Tagged CHARGE Syndrome, Congress (U.S. Legislature), expert, Health Policy, meeting cancellation, Preventive Care, RFK Jr., USPSTF

RFK Jr.; USPSTF; meeting cancellation; preventive care; health policy; HHS; Congress; expert panel integrity

Federally-Funded Cancer Research at a Perilous Crossroads: Deep Cuts Threaten Progress

4 months ago talkbio0Tagged AACR, Budgets, Cancer Research, Congress (U.S. Legislature), federal, Funding, Malignant neoplasm of lung, NIH Mouse, Pancreatic carcinoma, public health policy

federal funding; cancer research; NIH budget cuts; Congress; lung cancer; pancreatic cancer; AACR; public health policy

RFK Jr. Defends HHS Staff Cuts and Reorganization at House and Senate Hearings

5 months ago talkbio0Tagged Budgets, CHARGE Syndrome, Congress (U.S. Legislature), health coverage, HELP Committee, House Appropriations Committee, Medicaid, reorganization, RFK Jr., Senate, Staff

RFK Jr.; HHS; staff cuts; reorganization; Congress; House Appropriations Committee; Senate HELP Committee; budget cuts; Medicaid; health coverage

Congress Eyes Major PBM Reforms in Year-End Spending Bill

10 months ago talkbio0Tagged Benefit Managers, bipartisan, Congress, Congress (U.S. Legislature), Health care facility, Legislation, PBMs, Pharmaceutical Services, Pharmacy Benefit Manager, Prices, reforms, spending, year-end

Pharmacy Benefit Managers (PBMs), PBM reforms, healthcare costs, year-end spending bill, Congress, bipartisan legislation, transparency, drug prices.

Merus’s Petosemtamab Demonstrates Promising Efficacy in Expanded HNSCC Dataset

11 months ago talkbio0Tagged Clinical Trials, Congress (U.S. Legislature), ESMO, Head, Malignant Neoplasms, Merus, MRUS, N.V., Petosemtamab, Squamous cell carcinoma of the head and neck

Petosemtamab, HNSCC (Head and Neck Squamous Cell Carcinoma), Merus N.V. (MRUS), Clinical Trial Results, Cancer Treatment, ESMO Asia Congress 2024

Merus’ Petosemtamab Demonstrates Promising Efficacy in Head and Neck Cancer, Enhancing Its ‘Best-in-Disease’ Profile

11 months ago talkbio0Tagged Biclonics, Cancer of Neck, Clinical Trials, Congress (U.S. Legislature), Epidermal Growth Factor Receptor, ESMO, LGR5 gene, Merus, Petosemtamab

Petosemtamab, Head and Neck Cancer, Clinical Trials, Merus, ESMO Asia Congress 2024, Biclonics, EGFR and LGR5

Lantheus’ Phase 3 SPLASH Trial Results: 177Lu-PNT2002 Shows Promise but May Not Overtake Pluvicto

1 year ago talkbio0Tagged Congress (U.S. Legislature), ESMO, Lantheus, Phase 3 SPLASH, Pluvicto, PSMA, PSMA-positive metastatic castration-resistant prostate cancer

Lantheus, Phase 3 SPLASH Trial, 177Lu-PNT2002, PSMA-positive metastatic castration-resistant prostate cancer, ESMO Congress 2024, Pluvicto

ESMO 2024: IO Biotech’s IO102-IO103 Vaccine in Combination with Pembrolizumab Shows Promising Results in Head and Neck Cancer

1 year ago talkbio0Tagged biotech, Cancer of Neck, Congress (U.S. Legislature), ESMO, Immunotherapy, Io satellite, IO102-IO103, Keytruda, pembrolizumab, Therapeutic Cancer Vaccine

IO Biotech, IO102-IO103, Pembrolizumab (Keytruda), Head and Neck Cancer, ESMO Congress 2024, Therapeutic Cancer Vaccine, Immunotherapy

KEYTRUDA (Pembrolizumab) Plus Chemoradiotherapy Reduces Mortality Risk by 33% in High-Risk Locally Advanced Cervical Cancer

1 year ago talkbio0Tagged Chemoradiotherapy, Congress, Congress (U.S. Legislature), high-risk, Keytruda, Locally, Malignant tumor of cervix, Overall Survival, pembrolizumab

KEYTRUDA (pembrolizumab), Chemoradiotherapy (CRT), High-risk locally advanced cervical cancer, Overall survival (OS), European Society for Medical Oncology (ESMO) Congress 2024